Healthcare professionals are being urged to recognize that angioedema associated with ACE inhibitors is not always allergic in nature—a critical distinction that directly impacts patient outcomes. According to a safety alert from the UK Medicines and Healthcare products Regulatory Agency (MHRA), bradykinin-mediated angioedema does not respond to standard antihistamine or corticosteroid therapies, yet these medications remain commonly administered as first-line treatments. The challenge intensifies because delayed-onset angioedema can develop at any point during ACE inhibitor therapy, even after years of stable treatment, making early recognition essential. Clinicians must differentiate between bradykinin-mediated cases, which require specialist intervention with bradykinin antagonists, and histamine-mediated cases, which respond appropriately to conventional allergy management. This distinction prevents costly treatment delays and unnecessary medication exposure that could harm patients. The MHRA guidance emphasizes that understanding these two distinct pathways is fundamental to modern pharmacovigilance and patient safety protocols. Read the full article on GMJ Newsroom.
Was this article helpful?
